Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
- Certificates
Please try another search
Stocks Are Hot! Get 50% Off InvestingPro Now 🌞 CLAIM OFFER
Amgen to acquire Horizon for $26 billion as Sanofi drops bid - report
Author
Published Dec 12, 2022 05:30
© Reuters.
By Senad Karaahmetovic
Amgen (NASDAQ:AMGN) has agreed to acquire Horizon Therapeutics (NASDAQ:HZNP), according to Bloomberg News. Amgen agreed to pay $116.5 for each HZNP share, valuing the deal at about $26 billion.
If completed, Horizon would become Amgen’s largest-ever acquisition. The deal could be announced as soon as this week, although the talks could still fall apart, according to Bloomberg.
The Wall Street Journal reported first that Amgen is in advanced talks to buy Horizon for “well over $20 billion.”
Horizon accepted the bid from Amgen after French giant Sanofi SA (EPA:SASY) said it won’t proceed with an offer due to a high price. Johnson & Johnson (NYSE:JNJ) also pulled out from the race earlier this month.
Amgen’s $116.5 per share bid for Horizon represents a 20% premium to the firm’s closing price on Friday. Horizon shares soared over 27% on November 29 on the report that several large companies are discussing a takeover deal. The agreed price represents a 48% premium relative to HZNP’s closing price on November 28.
For Mizuho analysts, the takeover makes “strategic sense” due to two key reasons. First, Amgen’s Otezla and Enbrel are facing competition from Sotyktu and HZNP's portfolio “could help fill that gap as a growth driver for AMGN.”
Second, they argue, that an HZNP takeover “could potentially help Amgen manage its tax burden going forward."
“In 2014 HZNP acquired Vidara Therapeutics International, which moved Horizon to Ireland and reduced its tax bill substantially. AMGN is facing potentially higher taxes due to ongoing issues with its Puerto Rico facility and a deal with HZNP could perhaps help to mitigate this issue, in our view,” the analysts added.
Oppenheimer analysts added that the two companies have a complementary autoimmune pipeline. On the valuation, the analysts said earlier that the reasonable price for HZNP would be around $120 per share.
HZNP stock is up 14% to $111.00 per share in pre-open Monday while Amgen shares are down 0.8%.
Related Articles
Add Chart to Comment
Confirm Block
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
Report this comment
I feel that this comment is:
Comment flagged
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.